Osteoarthritis: 119. The Effectiveness of Exercise Therapy with and without Manual Therapy for Hip Osteoarthritis: A Multicentre Randomised Controlled Trial by French, Helen et al.
Results: The definition of vitamin D sufficiency according to our
reference laboratory is a 25(OH)D level of >75 nmol/L. Vitamin D status
was checked in a total of 85 patients (53 female; 32 male). The mean
age was 54.8 years (range: 19 - 86 years). A total of 90.6% patients
showed inadequate levels of 25(OH)D (87.5% of males and 92.5% of
females). 64.7% of patients had a 25(OH)D level < 50 nmol/L. 23.5% of
the total had a 25(OH)D level < 30 nmol/L.
Conclusions: The vast majority of rheumatology outpatients com-
plaining of polyarthralgia, polymyalgia or fatigue either as a primary
diagnosis or secondary to their main rheumatological diagnosis had
inadequate vitamin D levels. It should be noted that most of these
results were obtained in early autumn when it might be expected that
vitamin D levels would be at their peak. Almost a quarter of these
patients had very low vitamin D levels (<30 nmol/L).
Disclosure statement: The authors have declared no conflicts of
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117. A COMPARATIVE STUDY OF RENAL DYSFUNCTION IN
PATIENTS WITH RHEUMATOID ARTHRITIS AND
SERONEGATIVE INFLAMMATORY ARTHRITIS: STRONG
ASSOCIATION WITH CARDIOVASCULAR DISEASES AND
NOT WITH ANTI-RHEUMATIC THERAPIES, INFLAMMATORY
MARKERS OR DURATION OF ARTHRITIS
Muhammad Haroon1, Fahd Adeeb1, Joe Devlin1,
Donncha O´ Gradaigh1 and Frank Walker2
1Department of Rheumatology, Waterford Regional Hospital,
Waterford, Ireland; 2Department of Nephrology, Waterford Regional
Hospital, Waterford, Ireland
Background: Although, both rheumatoid arthritis and psoriatic arthritis
run a chronic progressive disease course, these differ in a multitude of
ways, such as, the anatomical localization of inflammatory lesions and
extra-articular manifestations. In this study, we tested whether these
obvious differences in disease characteristics are also reflected by
differences in renal dysfunction. To study this in more detail, we
performed a comparative study of the prevalence of CKD between
comparable patients with RA and seronegative arthritis, and tried to
explore any predictive factors for renal impairment.
Methods: Consecutive patients with peripheral joint disease (oligo and
polyarthritis) were recruited from our inflammatory arthritis clinics. We
divided patients in two groups: rheumatoid arthritis group and
seronegative inflammatory arthritis group. The cohort consisted of
183 patients [RA¼ 107, Seronegative arthritis¼76 (Psoriatic arthritis¼
69, undifferentiated oligoarthritis¼7)]. Estimated GFR was calculated
using the established MDRD equation. Demographic details, disease
specific characteristics, anti-rheumatic drugs, and the presence of
cardiovascular diseases were recorded.
Results: In total, 17.48% (n¼32) of the cohort had CKD, and among
them only 28% (9 out of 32) had a written diagnosis of CKD in their
medical records and 94% (30 of 32) of these patients were using
DMARDs, mainly methotrexate (65.6%, 21 out of 32). There was no
statistically significant variation between two groups as regards
baseline demographics, disease characteristics, use of anti-rheumatic
drugs, and the presence of individual cardiovascular diseases. We
found that eGFR and the presence of CKD were similar among these
groups. Among patients with CKD, 72% had undiagnosed CKD. The
mean age of patients with CKD did not differ significantly from patients
with normal GFR (52.80 vs. 51.96 years, p¼0.703). CKD patients were
more likely to have longer duration of the disease (mean 8.68 vs. 7.41
years, p¼0.042), and raised inflammatory markers (47% vs. 26%,
p¼0.018). No association of statistical significance was noted
between CKD and the use of corticosteroids, DMARDs and anti-TNF
agents. The association of cardiovascular diseases with CKD
remained significant after adjusting for confounders (age, gender,
duration of arthritis, high CRP, use of anti-rheumatic drugs).
Conclusions: Patients with inflammatory arthritis are more prone to
have CKD. This could have serious implications, as majority of
rheumatology patients use NSAIDs and different immunosuppressives,
such as methotrexate. No association of kidney dysfunction was noted
with inflammatory disease-specific characteristics, rather it appears to
have positive independent association with cardiovascular diseases
Disclosure statement: The authors have declared no conflicts of
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118. a1-ANTITRYPSIN IN FIBROMYALGIA: RESULTS OF A
RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND,
AND CROSS-OVER PILOT TRIAL
Cayetano Alegre1, Mireia Barcelo´1, Rossend Jardı´2,
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Background: Current hypothesis of fibromyalgia (FM) aetiology
includes neuroendocrine and inflammatory disorders. Several evi-
dences suggest that a1-antitrypsin (AAT) might play role in controlling
the inflammatory component of musculoskeletal connective tissue.
The purpose of this study was to assess clinical effect of a human
plasma-derived AAT concentrate in reducing pain severity of FM
patients.
Methods: This was a unicenter, prospective, randomized, placebo-
controlled, double-blind, and cross-over pilot trial (EudraCT number:
2005-004830-42). Subjects were randomly assigned to group A!B (to
receive human AAT at a dose regimen of 60 mg/kg of body weight
weekly) or group B!A (to receive equivalent volume of normal saline
solution -placebo- weekly) for 9 weeks (treatment period 1). After a
wash-out period of 6 weeks, the investigational products (IPs) were
changed in a cross-over fashion for 9 weeks (treatment period 2).
Finally, individuals were followed up during 6 weeks. All subjects were
required to meet the American College of Rheumatology 1990 criteria
for FM. Other treatments for FM were allowed, provided that these
remained unchanged (up to 25% of daily doses) during the study.
Primary efficacy endpoint was change on pain severity score,
assessed by a daily visual analogue scale (VAS) for pain. Secondary
outcome measures included tender points, Fibromyalgia Impact
Questionnaire, Medical Outcomes Study Short Form 36, Health
Assessment Questionnaire, Hospital Anxiety and Depression Scale,
and daily VAS for tiredness. Safety was assessed by reporting of
adverse drug reactions (ADRs).
Results: Thirteen adult individuals (mean age 47 years, mean duration
of FM 7 years) were allocated in group A!B (n¼ 7) or group B!A
(n¼ 6). Baseline demographics and clinical characteristics were
comparable between treatment groups. None subject presented AAT
congenital deficiency. All individuals receive concomitant medication
during the clinical trial, in most cases due to self-medication. Mean
change on the pain severity score in group A!B was 0.07 (SD¼ 1.13)
and in group B!A was -0.85 (SD¼1.99). No statistically significant
differences were observed in both groups: group A!B (p¼ 0.90) and
B!A (p¼ 0.40). No statistically significant differences were revealed
between treatment groups in both treatment periods: treatment period
1 (p¼0.26) and treatment period 2 (p¼0.96). Neither carryover effect
nor order effect were observed. Changes on secondary outcomes did
not evidence statistically significant differences between treatment
groups and periods. Both IPs were well tolerated with a low incidence
of only mild ADRs. No serious ADRs were reported.
Conclusions: In this pilot study, treatment with a human plasma-
derived AAT concentrate did not demonstrate significant improvement
over placebo on reducing pain severity and other symptoms of FM.
Further research should examine other FM subpopulations and drug
doses.
Disclosure statement: C.A. has received consultancy fees from
Pfizer, Esteve, Jazz Pharmaceuticals and Gru¨nenthal. S.C. and L.N.
are employees of Instituto Grifols S.A. All other authors have declared
no conflicts of interest.
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119. THE EFFECTIVENESS OF EXERCISE THERAPY
WITH AND WITHOUT MANUAL THERAPY FOR HIP
OSTEOARTHRITIS: A MULTICENTRE RANDOMISED
CONTROLLED TRIAL
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Background: Current evidence indicates that exercise therapy (ET)
has a short and medium-term benefit for hip osteoarthritis (OA), but
evidence is inconclusive regarding the effect of manual therapy (MT).
The primary aim of this randomised controlled trial was to determine
the effectiveness of ET with and without MT on clinical outcomes for
individuals with hip OA. A secondary aim was to ascertain the effect
of an 8-week waiting period on outcomes.
Methods: 131 men and women with hip OA recruited in four hospitals
were initially randomised to one of three groups: ET (n¼45), a
combination of ET and MT (n¼ 43) and wait-list control (n¼ 43). The
two intervention groups underwent individualised ET or ET/MT for 8
weeks. Patients in the control group waited 8 weeks and were
randomised to receive either ET or ET/MT after 9 week follow-up, and
pooled with original treatment group data: ET (n¼66) and ET/ MT
(n¼ 65). All participants were followed up at 9 and 18 weeks and the
control group was reassessed at 27 weeks (18 weeks post-treatment)
by the same blinded assessor. The primary outcome measure was the
Western Ontario and McMaster Universities Osteoarthritis Index
(WOMAC). Other outcomes included sit-to-stand, 50-foot walk test,
pain severity, hip range of motion (ROM), anxiety, depression, quality
of life (QOL), analgesic usage, physical activity, patient-perceived
change and patient satisfaction. Intention-to-treat analysis was
performed to determine within-group change and between-group
differences for the three groups at baseline and 9 weeks, and the two
treatment groups at baseline, 9 and 18 weeks.
Results: Eight patients (6.1%) were lost to follow-up at 9 weeks and
19 (14.5%) were lost to follow-up by 18 weeks. Both ET (n¼ 66) and
ET/MT groups (n¼ 65) showed significant within-group improvements
in WOMAC, pain severity, sit-to-stand and HROM measures at
9 weeks, which were still evident at 18 weeks. There was no significant
within-group change in anxiety, depression, QOL, analgesic usage,
50-foot walk test or physical activity. There was no significant
difference between the two intervention groups for any of the
outcomes.
Regarding the results of the original ET, ET/MT and control
group allocation, there was a significant improvement in one or both
ET and ET/MT groups compared with the control group in the same
outcomes, as well as patient perceived improvement at 9 weeks.
There was no significant difference between the three groups in
analgesic usage, WOMAC stiffness subscale, sit-to-stand and 50 foot
walk tests, QOL and physical activity. There was an overall deteriora-
tion in anxiety and depression scores.
Conclusions: The addition of MT to an 8 week programme of ET for
hip OA resulted in similar improvements in pain, function and ROM at
9 and 18 weeks. The significant improvement which occurred in the
same outcomes in the two treatment groups compared with a wait-list
control of 8 weeks has implications for waiting list management
Disclosure statement: The authors have declared no conflicts of
interest.
120. PREVALENCE AND INCIDENCE OF HIP
OSTEOARTHRITIS IDENTIFIED FROM DUAL ENERGY
XRAY ABSORPTIOMETRY IMAGES IN THE AUCKLAND
CALCIUM STUDY COHORT
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and David M. Reid1
1Division of Applied Medicine, University of Aberdeen, Aberdeen,
United Kingdom; 2Faculty of Medical and Health Sciences,
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Background: Osteoarthritis (OA) and osteoporosis are the two most
common musculoskeletal diseases in the aging population and its
relationship has long been debated. Dual energy Xray absorptiometry
(DXA) scanners are used to assess osteoporosis, but recently, DXA
images have also been shown to adequately assess OA. The purpose
of this study was to assess the prevalence and incidence of hip OA
(HOA) based on DXA images in a large study cohort from New
Zealand.
Methods: DXA scans of the hip (Lunar Expert, GE) taken at 30 month
intervals over 5 years from postmenopausal women participating the
Auckland Calcium Study were scored for the presence of HOA using
Kellgren Lawrence grades (KL). Images from the each subject were
visualised simultaneously, and the reader blinded to the scan order.
Progression was defined as follows: KL change of 1 grade, or if the
change detected was 1 KL grade, by correct sequential ordering of
images.
Results: 1420/1471 subjects had baseline hip DXA images available of
adequate quality to assess prevalence. Of those, HOA (KL2) was
present in 8.45% at baseline. Of the 1,187 subjects who had 2 DXA
scans, 13.5% were classified as having progressed by the study
criteria. Incident new HOA was 2.3% and 4.8% for 2.5 year and 5 year
follow-up respectively.
Conclusions: The prevalence and incidence of HOA determined by
DXA were comparable to those published in literature for radiographs.
DXA may have a role in monitoring hip osteoarthritis in studies
of osteoporosis/fracture risk.
Disclosure statement: The authors have declared no conflicts of
interest.
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Anushka Soni1, Eveline Nu¨esch2, Peter Juni2, Stephan Reichenbach2
and Paul Dieppe3
1Nuffield Department of Orthopaedics, Rheumatology and
Musculoskeletal Sciences, University of Oxford, Oxford,
United Kingdom; 2Division of Clinical Epidemiology and Biostatistics,
Institute of Social and Preventive Medicine, University of Bern, Bern,
Switzerland; 3Institute of Clinical Education Research, Peninsula
Medical School, Universities of Exeter and Plymouth, Plymouth,
United Kingdom
Background: It is widely accepted that osteoarthritis (OA) is a
heterogeneous condition and the value of epidemiological data to
identify clinically relevant phenotypes, to improve both understanding
of aetiology and management, has been recently highlighted [1]. A
recent study of short-term consistency of knee pain has revealed
patient subgroups with different characteristics [2], but little research
has focused on long-term patterns of both hip and knee pain.The aim
of this study was describe to the different phenotypes of hip and knee
pain over 8 years, in a population-based cohort of patients reporting
lower limb pain at the point of screening.
Methods: 1275 subjects (772 females, age 35-85yrs at baseline)
reporting lower limb pain on initial screening, with follow-up pain data
at 8 years were selected from the SASH cohort, a population-based
study of 28 080 people randomly selected from 40 general practices in
the south-west of England. The patterns of joint involvement taking
account of baseline, follow-up and overall change over time were
described.
Results: Frequencies of static patterns of pain were (baseline n (%),
follow-up n (%)): none (527(41), 310(24%)), unilateral knee (250(20),
140(11)), unilateral hip (136(11), 73(6)), contralateral hip and knee
(11(1), 26(2)), bilateral knee (193(15), 202(16)), bilateral hip (33(3), 55(4)),
ipsilateral hip and knee (53(4), 130(10)), three joints (48(4), 134(11)), four
joints (24(2), 205(16)). The change in patterns of pain over time are
summarised in Table 1.
Conclusions: This is the first study to describe long-term longitudinal
change in hip and knee pain. Several potential pain phenotypes
have emerged and may be associated with different predictors, which
would aid understanding of aetiology and inform management. Further
validation is needed in other cohorts.
Disclosure statement: The authors have declared no conflicts of
interest.
TABLE 1. Change in pain pattern over 8 years
Pain pattern N (%)
No joint pain 154 (13)
Stable unilateral or bilateral knee pain 113 (9)
Unilateral knee or hip pain becoming bilateral 63 (5)
New onset unilateral hip or knee pain 98 (8)
New onset bilateral hip or knee pain 92 (7)
Unilateral hip or knee pain 100 (8)
Four painful joints with none or single joint involvement at baseline 110 (9)
Resolved unilateral or bilateral hip or knee pain 101 (8)
Other pattern of reduced joint involvement 113 (9)
Other stable number of painful joints 97 (8)
Other increasing number of painful joints 234 (19)
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122. CHONDROCYTE CRF RECEPTOR EXPRESSION AND
UROCORTIN I MEDIATED CHONDROPROTECTION
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1Department of Biomedical Science, University of Westminster,
London, United Kingdom; 2Department of Molecular Pathology,
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Background: Nitric Oxide (NO) has been implicated in the pathology
of Osteoarthritis (OA) through the induction of chondrocyte apoptosis.
Several studies have demonstrated raised levels of NO in
Osteoarthritic cartilage suggesting that agents which protect against
NO-induced mitochondrial injury may have therapeutic potential. We
have previously demonstrated the production of Urocortin (Ucn I) in a
human chondrocyte cell line following treatment with various pro-
apoptotic stimuli and further shown that the exogenous administration
of Ucn I protects chondrocytes from NO induced apoptosis. The
current study demonstrates the expression of functional CRF receptor
variants and indicates the presence of possible intracellular mechan-
isms through which Ucn may exert its chondroprotective effect.
Methods: Monolayer cultures of C-20/A4 cells were maintained in a
Dulbecco’s MEM (DMEM) - based medium containing 10% foetal calf
serum (FCS) at 378C and 5% CO2. Flasks were allowed to reach
80% confluency, serum-starved overnight in 1% FCS DMEM then
treated with the NO donor SNAP, Ucn I and a-helical CRH (a CRFR
antagonist) for 6 hours. CRFR and KATP channel subunit expression
were analysed by RT-PCR and p42/p44 MAPK activation studied by
western blotting. Apoptotic cell death was assessed by Annexin V/PI
binding and TUNEL assay with necrosis assessed by LDH release.
Results: An increase in chondrocyte apoptosis was observed
following treatment of C-20/A4 cells with SNAP. Co-treatment with
Ucn I resulted in a decrease in apoptosis which was abrogated
following the addition of ahCRH suggesting the presence of CRF
receptor mediated protection in these cells. RT-PCR experiments
confirmed the expression of both CRFR1 and CRFR2 mRNA,
specifically the CRFR1a and CRFR2b splice variants, by C-20/A4
chondrocytes. The mRNA expression of both Kir and SUR subunits of
the mitochondrial ATP sensitive inwardly rectifying potassium channel
were also demonstrated. Western blotting demonstrated a Ucn
mediated increase in p42/44 MAPK activation.
Conclusions: Inhibition studies with ahCRH and RT-PCR analysis of
CRFR expression indicate the presence of two active forms of CRFR,
CRFR1a and CRFR2b by C-20/A4 chondrocytes. The observation that
these cells express both CRFR1 and CRFR2 is novel in that CRFR1 are
largely confined to the central nervous system in humans, but would
explain the greater potency of Ucn I in chondroprotection as this
peptide binds to both CRFR1 and CRFR2 whilst Ucn II and Ucn III are
selective CRFR2 ligands. These receptors provide a putative cell
surface binding site for Ucn family members to exert their cytopro-
tective effects which may be mediated through a mechanism involving
Kir 6.1-containing mitochondrial potassium channels. Moreover, the
activation of the p42/44 MAPK in C20-A4 cells following Ucn treatment
also suggest the involvement of other cytoprotective mechanisms
(e.g. cAMP and PKA modulated responses) in Ucn mediated
chondroprotection.
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Background: Osteoarthritis (OA) is the most common arthritis world-
wide and causes significant pain and disability. Current treatments
including NSAIDs and opioids have significant side-effects. There is an
urgent need for safe, long-term treatments for pain in OA. Recent
imaging studies have demonstrated that synovitis is very common in
OA of the knee and strongly associated with pain. Methotrexate (MTX)
is a safe and effective treatment for synovitis with good efficacy and
long-term safety in inflammatory arthritides. This 24-week open-label
study evaluated the effectiveness of methotrexate at pain reduction in
knee OA. We also assessed ultrasound-detected synovitis.
Methods: Inclusion criteria included pain VAS >40/100 mm in the last
3 months, ACR clinical criteria for OA, radiographic evidence of OA
and no inflammatory arthritis. Ultrasound at baseline and 24 weeks
assessed effusion and synovial thickness (mm) in 3 compartments of
the knee. Patients received methotrexate up to 20 mg per week for 24
weeks. Validated questionnaires assessed response to treatment.
Results: 30 patients were recruited; 86.7% female, mean (range) age
64.5 (53 to 85), median (range) disease duration 39 months (6 to 122),
median baseline pain VAS (IQR) 68 mm (44). 4 withdrew with side-
effects and 2 with inefficacy. At 12 weeks 10/20 (50%) patients had
achieved a 20% reduction in 48 hr pain VAS. Seven patients (35%)
achieved at least a 40% reduction in pain VAS. At 24 weeks 8/13
(61.5%) had achieved a 20% reduction; 5 (25%) had achieved a 40%
reduction; 3 patients (15%) had experienced a flare. Using non
parametric Wilcoxon tests, at 24 weeks there was a median (IQR)
improvement in 48 hr pain VAS of -21 mm (55.5) (Z¼0.91), a median
(IQR) improvement in patient disease activity VAS of -26 mm (43)
(Z¼2.59) and a median improvement in physician disease activity
VAS of -13.5 mm (48.3) (Z¼1.37). Imaging: All patients had synovitis
(effusion or synovial hypertrophy) at baseline (22/30 demonstrated
both pathologies). At baseline there were no clear associations
between synovitis and pain or effusion and pain. At 24 weeks a
median (IQR) change in total synovial thickness of 2.6 mm (3.2) and a
change in total effusion score of 1.8 mm (5.4) were noted. At 24
weeks the change in pain VAS was not substantively associated with
total effusion but there was some evidence of an association with the
maximum compartment score (rho¼0.462, p¼ 0.112, n¼ 13). There
was no significant association between change in baseline pain VAS at
24 weeks and baseline total synovitis (total rho¼ 0.115, p¼0.707,
n¼ 13).
Conclusions: As expected, ultrasound-detected synovitis at baseline
was prevalent in all patients. Preliminary results of this small, open
label study suggest good efficacy for MTX at pain reduction in OA knee
patients and a large randomised controlled trial is now warranted.
Disclosure statement: The authors have declared no conflicts of
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KNEE AND HIP OSTEOARTHRITIS AT AGE 63: ISOLATED
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Background: Radiographs are currently the main imaging modality
used in epidemiological studies of osteoarthritis (OA). However,
musculoskeletal ultrasound has distinct advantages over radiographs,
as it is more sensitive in the detection of osteophytes and can be used
to assess joint inflammation.
Objective: To measure the prevalence of OA of the hand, knee and hip
using ultrasound, among members of the Newcastle Thousand
Families birth cohort
Methods: 268 participants from a community cohort aged 63 (born
in May-June 1947), had the dominant hand, both knees and both
hips scanned by a trained musculoskeletal sonographer (AA; Esaote
Mylab 70 XVG). Protocols were derived from EULAR guidelines. The
presence of knee osteophytes was assessed at the tibial and femoral
sites, medially and laterally. Effusion size was measured in the
longitudinal supra-patellar position. The hip was imaged in the anterior
longitudinal plane and images scored for presence of osteophytes and
femoral head shape. The first CMC joint and MCP, PIP and DIP joints
of the index finger (dominant hand) were imaged for osteophytes in a
multiplanar manner.
Results: Prevalence of osteophytes in the dominant hand was high at
the DIP joint at 70.5% while it was 25.3%, 11.2% and 39.5% for index
PIP, index MCP and thumb base CMC joints, respectively. Hand OA
prevalence was higher among females compared to males (p¼0.005,
2). Prevalence of knee osteophytes was 21.3%, 22.8% and 27.6% for
right, left and ‘‘any’’ knee, respectively. There was no significant
difference of knee osteophyte prevalence between males and females
(p¼0.8, 2). The prevalence of knee effusions was 24.2% and 19.8%
in right and left knees, respectively; with males showing a non-
significant trend towards higher prevalence than females (p¼ 0.1, 2).
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The prevalence of hip OA was higher than described in radiographic
surveys, with 29.5%, 32.8% and 43.7% in right, left and ‘‘any’’ hip,
respectively. Males had a non-significant trend towards higher
prevalence of hip OA, (p¼0.2, 2). Generalised OA was defined as
hand OA plus knee and/or hip OA. Ultrasound evidence of generalised
OA (48%) and isolated hand OA (31%) were common, compared to
isolated hip or knee OA (5%) and both hip and knee OA (3%).
Conclusions: This is the first study to look at the prevalence of
ultrasound defined OA in the community. The higher prevalence of OA
in the hands and hips in this study, when compared to previous
radiographic studies, adds evidence to the idea that ultrasound is
more sensitive than radiographs in detecting OA, particularly for the
presence of osteophytes. The high prevalence of isolated hand OA
suggests that ultrasound defined hand OA may be a predictor of the
development of generalised OA. A study of longitudinal risk factors for
OA obtained prospectively in this cohort is underway.
Disclosure statement: The authors have declared no conflicts of
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Background: Osteoarthritis (OA) is a global clinical challenge for which
no effective disease-modifying agents currently exist. Proteinase
activated receptor-2 (PAR-2) is a cell surface receptor activated by
proteolytic cleavage, revealing a tethered ligand which binds to
extracellular loop 2 resulting in intracellular signalling. We previously
demonstrated a role for PAR-2 in adjuvant (1) and rheumatoid arthritis
(2). As increasing evidence points to an inflammatory component in OA
(3), in the present study we tested the hypothesis that PAR-2 may play
a role in the pathogenesis of OA.
Methods: Experimental osteoarthritis was induced in wild-type and
PAR-2-deficient mice (C57Bl/6J background) by sectioning the medial
menisco-tibial ligament. This leads to destabilization of the medial
meniscus (DMM) and development of a mild arthropathy. Cartilage
degradation and increased subchondral bone formation were
assessed histologically as indicators of OA pathology. In separate
cohorts of wild-type mice, PAR-2 activation was inhibited following
DMM by either treating with a PAR-2 antagonist (p520), or a
monoclonal antibody targeting the protease cleavage site of PAR-2
(SAM-11). An isotype antibody was administered in a further group as
a control for SAM-11.
Results: Following DMM surgery, PAR-2 was upregulated in chon-
drocytes of wild-type but not sham-operated mice. Wild-type mice
showed greater cartilage damage scores (26 9, meanSEM, n¼6)
and increased subchondral bone formation (13.5 2.3%) compared to
PAR-2 deficient mice (2.9 0.5 and 1.82.4% respectively, n¼5) four
weeks following DMM (P<0.01). Crucially, inhibition of PAR-2 in wild-
type mice, using either p520 or SAM-11, was equally effective at
reducing OA progression in vivo (P<0.01). Wild-type mice showed
further joint degradation 8 weeks after the induction of osteoarthritis,
but PAR-2-deficient mice were still protected. Therapeutic intervention
one week following DMM was also effective in preventing disease
progression.
Conclusions: Studies in PAR-2 deficient mice provide proof of
concept for a key role for PAR-2 in OA pathogenesis, whilst inhibition
of PAR-2 activation following induction of OA affords substantial
protection from cartilage and bone pathology. Together these findings
support PAR-2 as a novel therapeutic target in treatment of OA.
Funding: This work was supported by Arthritis Research UK (17728,
18901).
Disclosure statement: The authors have declared no conflicts of
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126. ENTHESITIS-RELATED ARTHRITIS: TWO DISTINCT
CLINICAL PHENOTYPES?
Corinne Fisher1, John Ioannou1 and Debajit Sen1
1Rheumatology, University College Hospital, London,
United Kingdom
Background: The ILAR classification criteria define enthesitis related
arthritis (ERA) as a subtype of juvenile idiopathic arthritis. It is the
subtype most similar to adult ankylosing spondylitis. Axial disease is
said to be a late feature, with lower limb arthritis and enthesitis
prominent early symptoms. There have been no observational studies
since the development of the ILAR criteria. The aim of this study was to
identify ERA patients with axial disease and compare their clinical
characteristics to those with peripheral disease.
Methods: Patients with ERA were identified from those attending our
adolescent rheumatology clinic. A retrospective case review was
undertaken and a database of clinical manifestations, radiology and
treatment compiled. A comparison of patients with confirmed axial
disease on MRI scan (n¼30) and those with no axial disease (n¼25)
was made.
Results: 55 patients (47 males, 8 females) with ERA were identified
according to the ILAR diagnostic criteria for JIA. 39 (70.9%) had
experienced inflammatory spinal pain, 15 (27.3%) at diagnosis.
Average time to inflammatory back pain was 2 years 8 months. The
average age of onset for those with axial disease was 11 years
7 months compared with 9 years 5 months for those without. Average
duration of ERA was 7 years in the axial disease group and 8 years 10
months in the non-axial group. HLA B27 status was known in 42/55
patients and was positive in 89.5% with axial disease and only 52.2%
with non-axial disease. Knee arthritis was common in both groups
(73.3% and 80%). As expected, lumbar spine and SIJ symptoms were
more common in the axial disease group (73.3% vs 36% and 73.3% vs
20% respectively). In addition, hip arthritis occurred more frequently
in this group (70% vs 52%) and was common at presentation (40%
vs 16%). In the non-axial disease group, ankle arthritis was frequent
(84% vs 33.3%), occurring at presentation in 32% (vs 10%). Enthesitis
and upper limb arthritis were also common in this group (68% vs
43.3% and 61.5% vs 41.3% respectively).Enthesitis occurred
frequently at disease onset (20% vs 3.3%). Extra-articular manifesta-
tions were only found in patients with axial disease (3 iritis and
5 inflammatory bowel disease). A higher proprtion of the axial disease
group were on anti-TNF therapy (48.3% vs 23.1%). Treatment with
DMARD alone was more common with non-axial disease (65.4% vs
37.9%).
Conclusions: In this cohort, there appear to be two distinct
phenotypes of ERA. The first are those with axial disease which
appears to be associated with HLA B27, hip arthritis and extra-
articular manifestations. This group developed ERA later and had a
shorter disease duration than those without axial disease. A higher
proportion needed anti-TNF therapy. In the second group, non-axial
disease was associated with with ankle arthritis, enthesitis and upper
limb symptoms. Further studies are needed to determine whether the
presence or absence of certain clinical features in ERA predict the
development of axial disease.
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127. ADULTS WITH JUVENILE IDIOPATHIC ARTHRITIS ARE
AT INCREASED CARDIOVASCULAR RISK
Iain Goff1, Elizabeth Coulson1 and Helen Foster1,2
1Department of Rheumatology, Newcastle upon Tyne Hospitals NHS
Trust, Newcastle upon Tyne, United Kingdom; 2Newcastle
Musculoskeletal Research Group, Newcastle University, Newcastle
upon Tyne, United Kingdom
Background: The increased prevalence of cardiovascular (CV)
disease in adults with chronic inflammatory disease is well reported,
is the leading cause of death in Rheumatoid arthritis (RA) and annual
iii90 Wednesday 13 April 2011, 12:45–14:15 Poster Viewing II
